XNAS
ILMN
Market cap39bUSD
Oct 20, Last price
267.93USD
1D
0.05%
1Q
36.43%
Jan 2017
110.88%
IPO
1,278.68%
Name
Illumina Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers cutting-edge sequencing and array technologies crucial for genetic and genomic analysis. The company's comprehensive offerings empower clients across numerous sectors, facilitating the integration of genomic solutions into both research and clinical applications. These span critical fields such as life sciences, oncology, reproductive health, and agriculture. Illumina's product suite encompasses analytical instruments and their associated consumables, complemented by a range of services including genotyping, sequencing, instrument support contracts, development and licensing partnerships, and cancer detection testing. Its extensive customer base comprises genomic research centers, academic bodies, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic labs, and consumer genomics enterprises. The company directly distributes its products across North America, Europe, Latin America, and the Asia-Pacific region, while also leveraging life-science distributors to reach markets in Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Related entities
Subsidiaries (5)
ILLUMINA CAMBRIDGE LIMITED
Illumina Singapore Pte. Ltd.
ILLUMINA INDIA BIOTECHNOLOGY PRIVATE LIMITED
ILLUMINA PRODUCTOS DE ESPANA SL
Illumina Switzerland GmbH
Key people
Scott Gottlieb
Independent Chairman of the Board · since 2025
Jacob Thaysen
Chief Executive Officer, Director · since 2023
Ankur Dhingra
Chief Financial Officer · since 2024
Patricia Leckman
Chief People Officer · since 2023
Steven Barnard
Chief Technology Officer · since 2023
Kevin Pegels
Chief of Global Operations · since 2021
Jakob Wedel
Chief Strategy and Corporate Development Officer · since 2024
Scott Davies
Chief Legal Officer, Secretary · since 2025
Independent Director · since 2016
Independent Director · since 2017
Independent Director · since 2012
Independent Director · since 2017
Independent Director · since 2025
Independent Director · since 2024
Philip Schiller
Independent Director · since 2017
Independent Director · since 2019
Independent Director · since 2023
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
5200 ILLUMINA WAY
SAN DIEGO, CA 92122
US
SAN DIEGO, CA 92122
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑00 | 2021‑00 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||